





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/900,379	07/06/2001	Hing C. Wong	44470 C1-CPA-C (71758) 4293		
	590 09/10/2002				
	DIKE, BRONSTEIN, ROBERTS AND CUSHMAN,			EXAMINER	
INTELLECTUAL PROPERTY PRACTICE GROUP EDWARDS & ANGELL, LLP. P.O. BOX 9169			DECLOUX, AMY M		
	OSTON, MA 02209		ART UNIT	PAPER NUMBER	
			1644	0	
			DATE MAILED: 09/10/2002	$\wp$	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary						
		09/900,379	WONG ET AL.			
	•	Examiner  Amus M. Do Cloury	Art Unit			
	The MAILING DATE of this communication app	Amy M. DeCloux	1644 correspondence address			
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status	Passansive to communication(s) filed on					
·	Responsive to communication(s) filed on Fhis action is <b>FINAL</b> . 2b)  Thi	· is action is non-final.				
,	,		proposition as to the morite is			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositio	n of Claims					
	laim(s) <u>51-59</u> is/are pending in the applicatio					
	a) Of the above claim(s) is/are withdrav	vn from consideration.				
	laim(s) is/are allowed.					
·	6) Claim(s) is/are rejected.					
	laim(s) is/are objected to.					
8) Claim(s) 51-59 are subject to restriction and/or election requirement.						
Application Papers						
•	9) The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.  If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. ☐ Certified copies of the priority documents have been received.						
2	2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
2) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) tion Disclosure Statement(s) (PTO-1449) Paper No(s) _	5) Notice of Informa	ary (PTO-413) Paper No(s) al Patent Application (PTO-152)			

1

Art Unit: 1644

ŝ.

## DETAILED ACTION

## Election/Restrictions

This application contains claims directed to the following patentably distinct species of the claimed invention:

- A) A multivalent MHC fusion complex comprising two or more linked MHC fusion complexes wherein the MHC fusion complex contains or does not contain the transmembrane and cytoplasmic domains of the MHC molecule. Applicant is required to specify whether the elected complex contains or does not contain the transmembrane and cytoplasmic domains of the MHC molecule.
- B) A multivalent MHC fusion complex comprising two or more linked MHC fusion complexes wherein the MHC fusion complex is or is not linked to an immunoglobulin. Applicant is required to specify whether the elected complex is or is not linked to an immunoglobulin. If a complex linked to an immunoglobulin is elected, applicant is required to elect a specific immunoglobulin, such as IgG as recited in Claim 53.
- C) A multivalent MHC fusion complex comprising two or more linked MHC fusion complexes wherein the MHC fusion complex contains specific amino acids that have chemically reactive side chains. Applicant is required to elect a complex modified to include specific amino acids that have chemically reactive side chains, such as His as recited in claim 57.

These species of fusion complexes are distinct because each species has a unique structure with distinct biophysical and chemical properties.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, all claims are generic in at least one aspect.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Art Unit: 1644

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy M. DeCloux whose telephone number is 703 306-5821. The examiner can normally be reached on M-F 8:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 703 308-3973. The fax phone numbers for the organization where this application or proceeding is assigned are 703 305-3014 for regular communications and 703 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308-0196.

Amy DeCloux, Ph.D. Patent Examiner, September 8, 2002 Patrick J. Nolan, Ph.D., Primary Patent Examiner,